{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-222937","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.762081+00:00","generated_at":"2026-05-31T02:57:06.422278+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sensei Biotherapeutics appoints Josiah Craver as principal financial officer","bullets":["Craver appointed principal financial and accounting officer effective Sept 17, 2024; previously SVP Finance since July 2024.","Base salary $360,000, annual bonus target 35%, and stock option for 80,000 shares vesting over 4 years.","Severance: six months salary if terminated without cause/good reason; 12 months salary plus bonus and equity acceleration upon change in control.","David Gaiero ceased serving as interim principal financial and accounting officer immediately."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-222937","json":"https://secwatch.observer/filing/0001193125-24-222937.json","markdown":"https://secwatch.observer/filing/0001193125-24-222937.md","text":"https://secwatch.observer/filing/0001193125-24-222937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524222937/0001193125-24-222937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524222937/d881257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:57:06.422278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c27dbbbf6f","claim":"David Gaiero departed as interim principal financial officer and principal accounting officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"In connection with such appointment, David Gaiero, who was serving as the Company’s principal financial officer and principal accounting officer on an interim basis, ceased serving in such capacities as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524222937/0001193125-24-222937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"interim principal financial officer and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"f60d5bb389","claim":"Josiah Craver was appointed as principal financial officer and principal accounting officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"On September 17, 2024, the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed Josiah Craver as the Company’s principal financial officer and principal accounting officer, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524222937/0001193125-24-222937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}